Franklin Resources’s Entrada Therapeutics TRDA Stock Holding History

Franklin Resources’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$140K	Buy	+11,102	New	+$127K	﹤0.01%	2864
2025 Q2	–	Sell	-16,290	Closed	-$147K	–	3133
2025 Q1	$147K	Hold	16,290	–	–	﹤0.01%	2763
2024 Q4	$282K	Hold	16,290	–	–	﹤0.01%	2529
2024 Q3	$290K	Hold	16,290	–	–	﹤0.01%	2499
2024 Q2	$232K	Buy	16,290 +1,971	+14%	+$28K	﹤0.01%	2522
2024 Q1	$203K	Buy	14,319 +1,113	+8%	+$15.7K	﹤0.01%	2589
2023 Q4	$199K	Buy	+13,206	New	+$196K	﹤0.01%	2352

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources's TRDA Position: Q1 2026 in Review

Franklin Resources opened a new position in Entrada Therapeutics (TRDA) in Q1 2026: 11,102 shares worth $140K. The stake represents ﹤0.01% of the portfolio and ranks #2864 among its holdings. This is a return to the name: Franklin Resources previously reported a position in TRDA as recently as Q1 2025.

Franklin Resources first reported a position in TRDA in Q4 2023 and has held it in 7 quarters since. The position peaked at $290K in Q3 2024. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

Franklin Resources held 11,102 shares of Entrada Therapeutics worth $140K as of Q1 2026.
Entrada Therapeutics was a new Franklin Resources position in Q1 2026.
Entrada Therapeutics made up ﹤0.01% of Franklin Resources's portfolio in Q1 2026, its #2864 holding.
Franklin Resources first reported a position in Entrada Therapeutics in Q4 2023 and has held it in 7 quarters since.
Franklin Resources's Entrada Therapeutics position peaked at $290K in Q3 2024.
120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Franklin Resources's 13F filing for Q1 2026, filed 13 May 2026.